Last reviewed · How we verify
buprenorphine sublingual film
Buprenorphine sublingual film, marketed by Alar Pharmaceuticals Inc., is an established treatment in the opioid dependency market. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | buprenorphine sublingual film |
|---|---|
| Sponsor | Alar Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Bundled Intervention - Phase 2 (PHASE4)
- INDV-6001 Multiple-Dose Pharmacokinetic Study (PHASE2)
- Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use (PHASE2)
- Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder (PHASE1)
- Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine (PHASE2, PHASE3)
- Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder (PHASE4)
- Medication Maintenance Therapy in Community Pharmacy Settings (PHASE2, PHASE3)
- Long Acting Buprenorphine Injection Compared to Sublingual Buprenorphine/Naloxone Films (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- buprenorphine sublingual film CI brief — competitive landscape report
- buprenorphine sublingual film updates RSS · CI watch RSS
- Alar Pharmaceuticals Inc. portfolio CI